World City Press – Lifestyle
Author:
LEADS BIOLABS CO., LTD.
LBL-047 Prioritized for Clinical Development in Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis
May 5, 2026
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
April 21, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
April 9, 2026